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The role of protein-tyrosine phosphorylation in the signal transduction of platelet activating factor (PAF) was investigated in rabbit platelets with 
a range of synthetic ompounds that inhibit protein-tyrosine kinases. In particular, erbstatin (IC,, u 20 #g/ml) abrogated a wide range of platelet 
responses to PAF, including tyrosine phosphorylation of cellular proteins, polyphosphoinositide turnover, activation of membranous protein k ase 
C, platelet aggregation, and serotonin secretion. With about a third of the potency of erbstatin, compound RG50864 also inhibited many of these 
responses, whereas at 100 pg/ml, genistein, 67OC88 and ST271 were without effect. Finally, the ability of thrombin to cause platelet aggregation 
and serotonin secretion was also compromised by erbstatin. 
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1. INTRODUCTION 
Like many other cytokines [I], platelet activating 
factor (PAF) triggers the rapid phospholipase C- 
catalyzed hydrolysis of phosphatidylinositol-4,5-bis- 
phosphate (PIP2) into diacylglycerol and inositol- 
trisphosphate [2-51. The ability of PAF to transiently 
increase the cytosolic free Ca2+ level in platelets may 
reflect its mobilization by inositol-trisphosphate [a]. 
The elevation of Ca2+ and,diacylglycerol has been link- 
ed with the activation of a family of Ca2+-activated, 
phospholipid-dependent protein kinase (PKC) 
isozymes [7]. Treatment of rabbit platelets with PAF 
leads to 2-3-fold increases in both the activities of 
cytosolic and membrane-bound forms of PKC within 
one minute [5,8]. The pivotal role that this kinase plays 
in platelet activation by PAF and other cytokines is im- 
plied by the ability of a range of PKC inhibitors to 
block such downstream responses to these agonists as 
cell aggregation and the release of mediators like 
serotonin [9- 121. 
Within seconds of exposure to human platelets to 
thrombin and collagen, enhanced tyrosine 
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phosphorylation of several proteins can be detected 
[13,14]. This implies that the activation of a protein- 
tyrosine kinase, possibly the receptors for thrombin 
and collagen or an associated kinase like ppw-“” [ 151, 
may participate in early signal transduction leading to 
platelet activation. The discovery by Rhee and his col- 
leagues [ 16- 181 that a PIPz-recognizing phospholipase 
C is tyrosine phosphorylated in cultured cells in 
response to platelet-derived growth factor and epider- 
mal growth factor, as well as in vitro by the recep- 
tor/kinases for these mitogens has raised the possibility 
that PIP2 breakdown is directly regulated by protein- 
tyrosine phosphorylation. While there is a good cor- 
relation between the ability of growth factors to induce 
both phospholipase C phosphorylation and PIP2 
hydrolysis, it is unknown whether the tyrosine 
phosphorylation is required for activation of the 
phospholipase. 
2. MATERIALS AND METHODS 
2.1. Materials 
Genistein [19] was purchased from Apin Chemicals. Erbstatin [20], 
2.5bis-(3,4-dimethoxybenzylidene)cyclopentanone [21] (67OC88), a- 
cyano-4-hydroxy-3,5-diisopropylcinnamamide [22] (ST271), and (Y- 
cyano-3,4dihydroxythiocinnamamide [23] (RG50864 also numbered 
12) were synthesized as published. All of these compounds were 
prepared as concentrated stock solutions in DMSO, except erbstatin, 
which was dissolved in ethanol. PAF, thrombin, histone Hl (type III- 
S), protamine sulphate and most other reagents were bought from 
Sigma (St. Louis, MO). [2-‘H]Inositol and [3H]serotonin were pur- 
chased from Amersham (Arlington Heights, IL), and [y-“P]ATP 
from ICN Radiochemicals. 
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2.2. Methods 
Rabbit platelets were isolated by the method of Pinckard et al. 
[Za]. Platelets at a concentration of 1 x lOs/ml were chahenged with 
PAF (100 PM), or thrombin (2 units/ml) at 37°C in Tyrodes buffer, 
pH 7.2. Following drug treatment, the 1% ~~~lubi~z~ 
microsomes from platelets were subjected to MonoQ 
chromatography, and the column extracts were assayed for protein 
kinase C activity [8]. 
The prelabelling of rabbit platelets with [3H]inositol for the 
polyph~phoinositide turnover studies was performed as indicated 
[S]. Cells (1.5 x 109/0.5 ml) were challenged with the protein-t~osine 
kinase inhibitors for 5 min, then with 100 pM PAF for 1 min. After 
1.8 ml of denaturing buffer were added, the various inositol 
phosphates were extracted and resolved by Dowex-1 (Bio-Rad) 
chromatography prior to quantitation of radioactivity as described 
by Watson et al. [25]. 
For the platelet aggregation studies, cells (2 x lO’/mi) were 
prepared in Tyrode’s buffer, pH 7.2 containing calcium chloride 
(1.3 mM). Aliquots (0.5 ml) were assayed for PAF-induced aggrega- 
tion in the absence or presence of the protein-tyrosine kinase in- 
hibitors using a Bio-Data aggregometer (Bio-Data, Hatboro, PA). 
These agonists and inhibitors in 50 ,ul of 0.25% BSA in Tyrode’s buf- 
fer were directly added to the platelets in a cuvet. Activities were 
measured as percent increase in light transmission. 
For the serotonin release studies, platelets (2 x log/ml) were in- 
cubated with 0.3 &X’ml of [‘Hlserotonin for 3 h at 37°C. The non- 
incorporated [3H]serotonin was removed by washing the platelets 
three times with Tyrode’s buffer. The platelets (2 x 108/ml) were 
preincubated in the absence and presence of the protein-tyrosine 
kinase inhibitors for 5 min and then challenged with 100 pM PAF for 
1 min before being pelleted in a microcentrifuge at lSOO0 rpm for 
15 s. The ra~~ctivity remaining in the supematant was quantitated 
and plotted against the initial radioactivity present in the cells. 
Following sodium-dodecyl-sulfate gel electrophoresis 1261, platelet 
proteins were transferred to a nitrocellulose membrane 1271. After 
overnight incubation in buffer containing 5% bovine serum albumin 
and 1% ovdbumin, the blots were incubated with a monoclonal an- 
tiphosphotyrosine antibody, PY-20 (ICN), followed by alkaline 
phospha~~~onju~ted goat anti-mouse IgG (C~biochem). Color 
development was done using S-brom~~oro-3-indoylphosphate 
and nitroblue tetraxolium (Bethesda Research Laboratories), follow- 
ing the manufacturer’s directions. 
3. RESULTS 
Rabbit platelets are exquisitely responsive to activa- 
tion by picomolar concentrations of PAF, and within 
a minute, an optimal dose of PAF (i.e. 100 PM) can 
trigger the release of more than 80% of total cellular 
serotonin (Fig. 1). This facile and highly sensitive assay 
was exploited to test the effects of potential protein- 
tyrosine kinase inhibitors on PAF responses in rabbit 
platelets. As shown in Fig. 1, preincubation of platelets 
for 5 min. with erbstatin at concentrations exceeding 
10 gg/ml inhibited subsequent PAF-induced serotonin 
release from the cells. Furthermore, thrombin-elicited 
serotonin secretion was similarly abolished by erbstatin 
(not shown). The inhibitor RG50864 also prevented 
PAF-induced release of serotonin with a third of the 
potency of erbstatin, whereas genistein, 67OC88 and 
ST271 at lOO~g/ml were without effect on secretion 
(not shown). All of these compounds have been 
reported to have negligible effects on protein- 
serine/threo~ne phospho~lation [19,22,23,28], while 
some exhibit selectivity towards different protein- 
1 oar 
Fig. 1. Dose-response for erbstatin inhibition of serotonin release 
from PAF-treated rabbit platelets. Cells prelabelled with 
[3H]serotonin were either untreated (A) or incubated for 5 min with 
0-50rg/ml erbstatin, and subsequently exposed for I min with 
100 pM PAF (0) prior to determination of released radioactivity. 
Values are the means f SD (n = 8). 
tyrosine kinases [22,23]. Since erbstatin produced the 
most sensitive inhibition of this action of PAF, our lat- 
ter experiments focused on the effect of this compound 
on other platelet responses to PAF challenge. 
Treatment of platelets with 100 pM PAF induces 
50% aggregation within 1 min (Fig. 2). Erbstatin at 
25 ,ug/ml had no effect on cell aggregation by itself, but 
it abolished the platelet clumping caused by 100 pM 
PAF (Fig. 2) and 2 units/ml thrombin (not shown). 
Protein kinase C has been implicated in the control 
of platelet aggregation and secretion. Within 1 min of 
either PAF or thrombin exposure to rabbit platelets, 
both the cytosolic and 1% NP40-solubilized particulate 
PKC activities become elevated 2-3-fold as measured 
in MonoQ-fractionated extracts [5,8]. Regardless of 
whether the Ca”, diacylglycerol and phosphatidyl- 
m 
r 
I 
1 min 
Fig. 2. Erbstatin inhibition of PAF-induced platelet aggregation. 
Platelet aggregation was measured as described in section 2. (A) Only 
buffer was added; [B) 100 pM PAF was added, (C) 25pggfml 
erbstatin was added, and then 2 min later (D) 100 pM PAF was 
added. Results are representative of five independent experiments. 
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Fig. 3. Erbstatin inhibition of PAF stimulation of particulate-derived 
protein kinase C activity. Washed platelets were preincubated for 
5 min with O-50,ug/ml erbstatin, and subsequently treated for an 
additional min with 100 pM PAF prior to harvesting. MonoQ 
chromatography of 0.5 mg of 1% NP40-solubilized particulate 
protein from the platelet extracts was performed, and the activity of 
PKC in the peak fractions (0.26-0.34 M NaCl) was measured 
towards histone Hl in the presence of Ca*‘, diolein and 
phosphatidylserine (A), and protamine sulfate in the absence of these 
cofactors (0). Less than 5% of the histone Hl phosphorylating 
activity was detected in the absence of Ca*+, diolein and 
phosphatidylserine (not shown). 
serine-dependent histone Hl phosphorylating or cofac- 
tor-independent protamine phosphorylating activities 
of PKC were assessed, the ability of PAF to stimulate 
the particulate-derived PKC activity was blocked by 
erbstatin concentrations exceeding 10 pg/ml (Fig. 3). 
Similarly, the enhanced cytosolic PKC activity from 
PAF-treated platelets was also lost if the cells were 
pretreated with erbstatin (not shown). 
The erbstatin-mediated inhibition of PKC activation 
by PAF indicated that this compound might also in- 
terfere with the ability of PAF to induce PIP2 
breakdown, since this has been implicated as the 
preceding step in the signal transduction pathway 
leading to PKC. As shown in Fig. 4, at 5 pg/ml and 
higher concentrations of erbstatin, PAF-induced for- 
mation of inositol mono-, bis- and trisphosphates was 
progressively inhibited. 
As thrombin and collagen had been shown to 
stimulate protein-tyrosine phosphorylation in human 
platelets [ 13,141, and the erbstatin experiments implied 
that this form of covalent modification might mediate 
PAF action, the ability of PAF to stimulate the tyrosine 
phosphorylation of rabbit platelet proteins was examin- 
ed. PAF treatment of the platelets led to the rapid 
phosphorylation of several polypeptides as assessed by 
Western blotting with anti-phosphotyrosine antibodies 
(Fig. 5). Although not shown in this figure, a parallel 
incubation with antiphosphotyrosine antibodies in the 
presence of 2 mM phosphotyrosine completely 
eliminated the labelling, whereas 2 mM phosphoserine 
only slightly decreased this signal. Phosphoamino acid 
analysis performed on at least 8 phosphoproteins 
whose phosphorylations were increased in response to 
PAF in 32P-labelled cells confirmed that they were 
tyrosine phosphorylated (not shown). The major 
180 
160 
F T 
40- 
2:t,<J 
50 
Erbstatin cont. (pg/ml) 
Fig. 4. Erbstatin inhibition of PAF-induced polyphosphoinositide 
breakdown. Rabbit platelets that were prelabelled with [3H]inositol 
were subsequently incubated for 5 min in the presence of O-50 fig/ml 
erbstatin, and subsequently treated for 1 min with 100 pM PAF prior 
to harvesting. The percent increases of PAF-induced incorporation 
of radioactivity into inositol mono- (o), bis- (m) and trisphosphate 
(0) are shown. Values are the means f SD of at least 10 
determinations per point. 
polypeptides whose phosphorylation was stimulated by 
PAF and inhibited by-erbstatin preincubation, are in- 
dicated in Fig. 5. The dose-response of erbstatin in- 
hibition of several polypeptides generally correlated 
with its inhibitory action on the other platelet responses 
to PAF. 
4. DISCUSSION 
Erbstatin was originally identified in the medium of 
an actinomycete as a compound that inhibited the 
autophosphorylation of the EGF receptor in mem- 
branes of A431 epidermoid carcinoma cells with an 
I& < 2.5 pg/ml [29]. Unlike genistein, which acts as 
a competitive inhibitor with respect to ATP [ 191, erb- 
statin may compete instead with the phosphoacceptor 
protein to reduce its phosphorylation by the EGF 
receptor/protein-tyrosine kinase [28]. The protein- 
tyrosine kinase inhibitor erbstatin was found to inhibit 
all of the PAF-stimulated responses measured in rabbit 
platelets with an ICSO of -20 pg/ml. This is about 30 
times the concentration reported for 50% inhibition of 
the EGF receptor/protein-tyrosine kinase [28]. On the 
other hand, a wide range of erbstatin analogs [23] have 
been shown to inhibit the insulin receptor/protein- 
tyrosine kinase with lOO-700-fold less potency than the 
EGF receptor. It may be that another erbstatin analog, 
not tested in this study, could serve to better inhibit 
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Fig. 5. Immunoblot with antiphosphotyrosine antibodies of 
phosphoproteins from PAF-treated platelets incubated with 10 or 
25 pg/ml erbstatin. Washed platelets were untreated (lanes 1 and 6), 
or treated with lO,ug/ml erbstatin (lanes 2 and 7), 50 pM PAF for 
1 min (lanes 3 and 8), lOpg/ml erbstatin for 5 min followed by 
50 pM PAF (lanes 4 and 9), or 25 fig/ml erbstatin for 5 min followed 
by 50 pM PAF for 1 min (lanes 5 and 10). Cells were rapidly 
centrifuged and the pellets frozen. Pellets were solubilized in SDS 
sample buffer and the equivalent of 8 x lo6 cells were loaded per lane 
on a 7.5% polyacrylamide gel and electrophoresed. Lanes l-5 are 
from a Coomassie blue-stained gel and lanes 6-10 are from a 
Western blot probed with antiphosphotyrosine antibodies. The major 
polypeptides whose labelling were increased in response to PAF and 
at least partially inhibited by erbstatin are indicated by letters. Their 
M,s are as follows: A, 215000; B, 172000; C, 137000; D, 123000; E, 
108000; F, 70000; G, 56000. 
~~60”” or whatever kinase is stimulated in response to 
PAF in platelets. RG50864, which inhibited the PAF 
responses in platelets with about 3-fold less potency 
than erbstatin, has been reported to inhibit the EGF 
receptor/protein-tyrosine kinase about three times 
more strongly than erbstatin [23]. 
Our findings indicate that increased protein-tyrosine 
phosphorylation is an important component in the 
post-receptor signal transduction system for PAF, and 
quite possibly thrombin. While treatment of platelets 
with erbstatin was not able to completely inhibit the in- 
creased tyrosine phosphorylation in response to PAF, 
it was clear that phosphorylation of a number of 
polypeptides was diminished by this inhibitor. Since the 
receptors for PAF and thrombin have not yet been 
isolated, it remains feasible that they feature protein- 
tyrosine kinase catalytic domains or alternatively they 
may associate with protein-tyrosine kinases. Akin to 
the EGF and PDGF receptors [ 16-181, the tyrosine 
phosphorylation of an associated phospholipase C 
might facilitate the hydrolysis of PIP2 and activation of 
PKC. 
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